Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.

Search

BIVICTRIX THERAPEUTICS PLC

BVX:JPJ
/
11.50
GBX
Professional, scientific & technical services

Description

BiVictriX Therapeutics Ltd (“BVX”) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX’s first-in-class Bi-Cygni® bispecific Antibody Drug Conjugates (“ADCs”) combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.

Company Details

Incorporated​
15 February 2016
Securities in Issue​
82,526,088
Market Cap
£9.08M
Contact Details
E-Mail
info@bivictrix.com
Address
Mereside Alderley Park, Alderley Edge, Manchester SK10 4TG

Company Snapshot

Status
Live
Dealing Restrictions​
None
Price
11.50
Ticker
BVX:JPJ
Class
Ord
Settlement
CREST
Industy
Professional, scientific & technical services
Country
United Kingdom
Company Number
10005270
ISIN
GB00BNXH3K91
Currency
GBX

Trading Results

DateQuantityMid. Price GBX
18/10/202448,28210.50
30/09/202450,00011.50
16/09/2024100,00011.00
16/09/2024150,00011.00

Management Information

Tiffany Thorn
Tiffany Thorn
Chief Executive Officer
Dr Michael Kauffman
Dr Michael Kauffman
Non-Executive Chairman
Prof. Robert Hawkins
Prof. Robert Hawkins
Independent Non-Executive Director
Susan Lowther
Susan Lowther
Independent Non-Executive Director
Drummond Paris
Drummond Paris
Senior Independent Non-Executive Director

TRANSACTING ON JP JENKINS

‘Trading on JP Jenkins is done via a matched bargain facility, this means that on instruction from your ‘Broker’ we will endeavour to match your shares against other buyer(s) or seller(s) who are also looking to transact. Requests to trade are performed on an availability basis, should an instruction be cancelled, altered or amended in anyway by an instruction from your broker then it shall lose its active place in the queue and reset to the end of list. JP Jenkins receives orders from brokers electronically via a FIX message or should your broker not have a FIX connection to our platform via telephone. If you do not have a UK registered stockbroker you will find a list of brokers that we have worked with to download here. You will also find a list of UK brokers at the bottom of this page and their contact details should you need to appoint one. JP Jenkins can ONLY take instruction to transact from a UK-registered stockbroker and cannot offer investment advice into companies displayed on our website. If you are unsure about trading please consult a financial advisor or wealth manager to assist you in determining what is right for you

How to Trade​

Trading with JP Jenkins

Trading Instructions:
To buy and sell shares in this company via JP Jenkins, you will need to use a regulated UK stockbroker.

For a comprehensive list of brokers click here.

Over 40 UK brokers regularly connect with our platform.
If you are based overseas and are interested in participating then please contact us directly by emailing info@jpjenkins.com or by calling 0207 469 0937
Trades take place through our central counterparty partner. There is a fee of 1.5% of the transaction price which is charged to both buyers and sellers and a £25 transaction fee. Your broker may also apply charges.

Please note, when purchasing shares Stamp Duty Reserve Tax (“SDRT”) may be applicable.